MDGL RSI Chart
Last 7 days
-6.5%
Last 30 days
-19.3%
Last 90 days
2.0%
Trailing 12 Months
-21.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2021 | 2.6M | 1.5M | 743.0K | 363.0K |
2020 | 9.9M | 8.1M | 6.1M | 4.3M |
2019 | 10.0M | 11.8M | 11.8M | 11.0M |
2018 | 1.2M | 2.3M | 4.9M | 7.7M |
2017 | 0 | 0 | 0 | 558.0K |
2016 | 0 | 0 | 0 | 0 |
2012 | 0 | 0 | 0 | 0 |
2011 | 12.4M | 9.9M | 8.2M | 7.6M |
2010 | 0 | 101.1M | 58.0M | 14.8M |
2009 | 0 | 0 | 0 | 144.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 08, 2024 | taub rebecca | acquired | 25,288 | 9.45 | 2,676 | pres., r&d, and cmo |
Apr 08, 2024 | friedman paul a | sold | -6,467,490 | 246 | -26,270 | - |
Apr 08, 2024 | friedman paul a | acquired | 248,252 | 9.45 | 26,270 | - |
Apr 08, 2024 | taub rebecca | sold | -658,258 | 245 | -2,676 | pres., r&d, and cmo |
Apr 05, 2024 | taub rebecca | acquired | 259,932 | 9.45 | 27,506 | pres., r&d, and cmo |
Apr 05, 2024 | friedman paul a | acquired | 260,943 | 9.45 | 27,613 | - |
Apr 05, 2024 | friedman paul a | sold | -6,721,080 | 243 | -27,613 | - |
Apr 05, 2024 | taub rebecca | sold | -6,693,790 | 243 | -27,506 | pres., r&d, and cmo |
Apr 04, 2024 | taub rebecca | acquired | 175,175 | 9.45 | 18,537 | pres., r&d, and cmo |
Apr 04, 2024 | taub rebecca | sold | -4,502,820 | 242 | -18,537 | pres., r&d, and cmo |
Which funds bought or sold MDGL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 16, 2024 | Overbrook Management Corp | new | - | 301,755 | 301,755 | 0.08% |
Apr 16, 2024 | Congress Park Capital LLC | new | - | 320,448 | 320,448 | 0.14% |
Apr 15, 2024 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | new | - | 259,830 | 259,830 | -% |
Apr 15, 2024 | ATLAS CAPITAL ADVISORS LLC | new | - | 267 | 267 | -% |
Apr 12, 2024 | Westend Capital Management, LLC | new | - | 1,068 | 1,068 | -% |
Apr 11, 2024 | Rheos Capital Works Inc. | new | - | 29,432,000 | 29,432,000 | 1.41% |
Apr 11, 2024 | Fortitude Family Office, LLC | unchanged | - | 36.00 | 267 | -% |
Apr 05, 2024 | NBC SECURITIES, INC. | unchanged | - | 1,000 | 12,000 | -% |
Apr 05, 2024 | GAMMA Investing LLC | added | 50.00 | 1,470 | 3,204 | -% |
Apr 05, 2024 | CWM, LLC | added | 73.58 | 13,000 | 25,000 | -% |
Unveiling Madrigal Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Madrigal Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 39.5B | 6.8B | -8.38 | 5.77 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.3B | 1.8B | -41.56 | 10.01 | ||||
BMRN | 17.1B | 2.4B | 101.85 | 7.06 | ||||
INCY | 11.8B | 3.7B | 19.8 | 3.2 | ||||
MID-CAP | ||||||||
APLS | 5.8B | 396.6M | -10.96 | 14.6 | ||||
BBIO | 4.4B | - | -6.72 | 60.35 | ||||
AXSM | 3.3B | 270.6M | -13.8 | 12.2 | ||||
ACAD | 2.8B | 726.4M | -46.22 | 3.9 | ||||
ARWR | 2.8B | 240.7M | -9.4 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.41 | 4.74 | ||||
NVAX | 544.4M | 983.7M | -1 | 0.55 | ||||
CRBP | 389.6M | 881.7K | -8.73 | 466.16 | ||||
INO | 258.5M | 4.9M | -1.91 | 53.11 | ||||
IBIO | 6.6M | 2.1M | -0.24 | 2.14 |
Madrigal Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 | 2016Q4 |
Revenue | -13.3% | 52,000 | 60,000 | 91,000 | 160,000 | 432,000 | 823,000 | 1,204,000 | 1,870,000 | 2,214,000 | 2,766,000 | 3,005,000 | 3,039,000 | 2,979,000 | 2,821,000 | 1,166,000 | 705,000 | 216,000 | 174,000 | 92,000 | 76,000 | 59,000 |
Operating Expenses | 2.3% | 64,601,000 | 63,160,000 | 61,742,000 | 52,979,000 | 59,555,000 | 58,786,000 | 50,327,000 | 38,005,000 | 29,954,000 | 24,195,000 | 22,704,000 | 18,119,000 | 14,454,000 | 11,333,000 | 7,826,000 | 7,069,000 | - | - | - | - | - |
S&GA Expenses | 41.3% | 11,712,000 | 8,287,000 | 10,110,000 | 7,209,000 | 6,126,000 | 5,494,000 | 5,639,000 | 4,605,000 | 5,044,000 | 4,748,000 | 7,110,000 | 5,746,000 | 5,583,000 | 5,122,000 | 2,717,000 | 1,871,000 | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -2.3% | -64,549,000 | -63,100,000 | -61,651,000 | -52,546,000 | -59,123,000 | -57,963,000 | -49,023,000 | -36,135,000 | -27,740,000 | -21,429,000 | -19,699,000 | -15,080,000 | -11,475,000 | -8,512,000 | -6,460,000 | -6,364,000 | - | - | - | - | - |
Net Income Margin | -2.3% | -325 | -318 | -153 | -83.49 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -5.6% | -48,164,000 | -45,606,000 | -46,883,000 | -43,473,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | 169.2% | 641 | 238 | 302 | 332 | 363 | 159 | 216 | 223 | 273 | 305 | 328 | 310 | 287 | 340 | 388 | 411 | 442 | 456 | 470 | 480 | 485 |
Current Assets | 170.6% | 637 | 235 | 302 | 331 | 361 | 157 | 215 | 221 | 272 | 303 | 326 | 308 | 285 | 338 | 387 | 409 | 440 | 455 | 469 | 478 | 485 |
Cash Equivalents | 61.0% | 100 | 62.00 | 77.00 | 113 | 332 | 59.00 | 53.00 | 42.00 | 36.00 | 49.00 | 34.00 | 44.00 | 54.00 | 109 | 62.00 | 67.00 | 47.00 | 89.00 | 73.00 | 47.00 | 57.00 |
Net PPE | 135.7% | 2.00 | 1.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 9.0% | 235 | 216 | 199 | 182 | 165 | 148 | 133 | 77.00 | 77.00 | 70.00 | 57.00 | 49.00 | 47.00 | 50.00 | 45.00 | 26.00 | 25.00 | 16.00 | 13.00 | 11.00 | 8.00 |
Current Liabilities | 18.9% | 119 | 100 | 100 | 98.00 | 116 | 99.00 | 84.00 | 77.00 | 77.00 | 69.00 | 57.00 | 49.00 | 47.00 | 49.00 | 45.00 | 26.00 | 25.00 | 15.00 | 12.00 | 10.00 | 8.00 |
Long Term Debt | 0.7% | 115 | 115 | 99.00 | 84.00 | 49.00 | 49.00 | 49.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | 0.7% | 115 | 115 | 99.00 | 84.00 | 49.00 | 49.00 | 49.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | 1721.8% | 405 | 22.00 | 104 | 150 | 197 | 11.00 | 84.00 | 146 | 196 | 235 | 271 | 261 | 240 | 290 | 343 | 385 | 417 | 440 | 457 | 469 | 477 |
Retained Earnings | -9.2% | -1,336 | -1,224 | -1,125 | -1,039 | -962 | -876 | -795 | -724 | -667 | -602 | -539 | -478 | -425 | -366 | -308 | -259 | -223 | -195 | -174 | -154 | -139 |
Additional Paid-In Capital | 39.7% | 1,741 | 1,246 | 1,229 | 1,190 | 1,160 | 888 | 880 | 871 | 863 | 838 | 810 | 739 | 665 | 656 | 650 | 644 | 640 | 636 | 631 | 623 | 617 |
Shares Outstanding | 7.6% | 20.00 | 18.00 | 18.00 | 18.00 | 18.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 16.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 3,158 | - | - | - | 985 | - | - | - | 819 | - | - | - | 1,130 | - | - | - | 884 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 5.9% | -79,933 | -84,920 | -75,310 | -84,067 | -58,515 | -59,069 | -57,360 | -49,913 | -48,051 | -45,556 | -46,881 | -43,429 | -54,947 | -47,850 | -24,258 | -30,506 | -12,282 | -11,324 | -11,540 | -6,478 | -6,265 |
Share Based Compensation | 17.3% | 14,852 | 12,660 | 10,973 | 11,250 | 8,082 | 8,122 | 7,944 | 7,477 | 6,356 | 6,242 | 8,179 | 6,096 | 5,134 | 5,061 | 5,689 | 4,846 | 4,032 | 4,950 | 7,755 | 6,022 | 5,119 |
Cashflow From Investing | -821.4% | -362,123 | 50,199 | -3,732 | -186,864 | 66,387 | 65,137 | 19,236 | 55,926 | 15,643 | 40,091 | -27,325 | -33,464 | -4,798 | 94,753 | 19,365 | 50,460 | -30,507 | 28,267 | 36,438 | -3,491 | 24,988 |
Cashflow From Financing | 2351.1% | 479,916 | 19,580 | 42,930 | 52,690 | 264,337 | - | 49,114 | - | 19,503 | 21,099 | 63,541 | 67,094 | 4,629 | 350 | 109 | - | - | 35.00 | 117 | 83.00 | 610 |
Consolidated Statements of Operations - USD ($) | 3 Months Ended | 12 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2023 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | |||||||||||
Total revenues | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 |
Operating expenses: | |||||||||||
Research and development | 70,640,000 | 70,951,000 | 68,605,000 | 62,154,000 | 70,742,000 | 68,271,000 | 58,499,000 | 47,929,000 | 272,350,000 | 245,441,000 | 205,164,000 |
General and administrative | 46,536,000 | 27,583,000 | 17,845,000 | 16,182,000 | 14,557,000 | 12,141,000 | 11,774,000 | 9,658,000 | 108,146,000 | 48,130,000 | 37,318,000 |
Total operating expenses | 117,176,000 | 98,534,000 | 86,450,000 | 78,336,000 | 85,299,000 | 80,412,000 | 70,273,000 | 57,587,000 | 380,496,000 | 293,571,000 | 242,482,000 |
Loss from operations | (117,176,000) | (98,534,000) | (86,450,000) | (78,336,000) | (85,299,000) | (80,412,000) | (70,273,000) | (57,587,000) | (380,496,000) | (293,571,000) | (242,482,000) |
Interest income | 8,953,000 | 3,298,000 | 3,551,000 | 3,776,000 | 1,076,000 | 717,000 | 323,000 | 69,000 | 19,578,000 | 2,185,000 | 363,000 |
Interest expense | (3,971,000) | (3,504,000) | (2,901,000) | (2,336,000) | (1,682,000) | (1,502,000) | (780,000) | 0 | (12,712,000) | (3,964,000) | 0 |
Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 273,000 |
Net loss | $ (112,194,000) | $ (98,740,000) | $ (85,800,000) | $ (76,896,000) | $ (85,905,000) | $ (81,197,000) | $ (70,730,000) | $ (57,518,000) | $ (373,630,000) | $ (295,350,000) | $ (241,846,000) |
Net loss per common share: | |||||||||||
Basic net loss per common share (in dollars per share) | $ (5.68) | $ (5.34) | $ (4.69) | $ (4.23) | $ (4.98) | $ (4.75) | $ (4.14) | $ (3.36) | $ (19.99) | $ (17.23) | $ (14.63) |
Diluted net loss per common share (in dollars per share) | $ (5.68) | $ (5.34) | $ (4.69) | $ (4.23) | $ (4.98) | $ (4.75) | $ (4.14) | $ (3.36) | $ (19.99) | $ (17.23) | $ (14.63) |
Basic weighted average number of common shares outstanding (in shares) | 19,760,842 | 18,476,414 | 18,310,952 | 18,187,924 | 17,237,517 | 17,103,395 | 17,103,395 | 17,103,395 | 18,687,774 | 17,137,201 | 16,535,188 |
Diluted weighted average number of common shares outstanding (in shares) | 19,760,842 | 18,476,414 | 18,310,952 | 18,187,924 | 17,237,517 | 17,103,395 | 17,103,395 | 17,103,395 | 18,687,774 | 17,137,201 | 16,535,188 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 99,915,000 | $ 331,549,000 |
Marketable securities | 534,216,000 | 27,225,000 |
Prepaid expenses and other current assets | 3,150,000 | 2,595,000 |
Total current assets | 637,281,000 | 361,369,000 |
Property and equipment, net | 1,553,000 | 601,000 |
Right-of-use asset | 1,713,000 | 602,000 |
Total assets | 640,547,000 | 362,572,000 |
Current liabilities: | ||
Accounts payable | 28,041,000 | 23,831,000 |
Accrued expenses | 89,980,000 | 91,461,000 |
Lease liability | 527,000 | 602,000 |
Total current liabilities | 118,548,000 | 115,894,000 |
Long term liabilities: | ||
Loan payable, net of discount | 115,480,000 | 49,289,000 |
Lease liability | 1,186,000 | 0 |
Total long term liabilities | 116,666,000 | 49,289,000 |
Total liabilities | 235,214,000 | 165,183,000 |
Stockholders’ equity: | ||
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at December 31, 2023 and December 31, 2022; 2,369,797 and 2,369,797 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 0 | 0 |
Common stock, par value $0.0001 per share authorized: 200,000,000 at December 31, 2023 and December 31, 2022; 19,875,427 and 18,102,523 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 2,000 | 2,000 |
Additional paid-in-capital | 1,741,153,000 | 1,160,079,000 |
Accumulated other comprehensive income (loss) | 468,000 | (32,000) |
Accumulated deficit | (1,336,290,000) | (962,660,000) |
Total stockholders’ equity | 405,333,000 | 197,389,000 |
Total liabilities and stockholders’ equity | $ 640,547,000 | $ 362,572,000 |
 | madrigalpharma.com |
---|---|
 | Biotechnology |
 | 92 |